Sino Biopharmaceutical Limited's high P/S ratio may not be j...
Sino Biopharmaceutical Limited's high P/S ratio may not be justified due to its slower revenue growth. Investors may hope for a business turnaround, but analysts lack confidence. The weak revenue outlook could risk the share price and shareholder investments.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000225beae9ba9bea.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment